FENNEC PHARMACEUTICALS INC. (FENC) 8-K Current Report: March 16, 2026
Filed: March 16, 2026
Health Care
Biological Products, (No Diagnostic Substances)FENNEC PHARMACEUTICALS INC. (FENC) 8-K current report filed with SEC EDGAR on March 16, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 8.01: Other Events
FENNEC PHARMACEUTICALS INC. 8-K Mar 16, 2026 Event Analysis
Item 8.01 · Other Events
- • Settlement with Cipla grants PEDMARK® exclusivity protection through September 1, 2033, blocking generic sodium thiosulfate entry
- • License Agreement resolves patent litigation (D.N.J. Case No. 2:23-cv-00123) — no damages or royalties mentioned, each party bears own costs
- • "Earlier entry under specified circumstances" clause introduces conditional risk to the 2033 exclusivity date — terms not disclosed
- • PEDMARK® is Fennec's sole commercial product; extended generic-free runway materially protects revenue through 2033
Other FENNEC PHARMACEUTICALS INC. 8-K Filings
Get deeper insights on FENNEC PHARMACEUTICALS INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.